A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome.
Author(s): George CF, Feldman N, Zheng Y, Steininger TL, Grzeschik SM, Lai C, Inhaber N
Affiliation(s): University of Western Ontario, London Health Sciences Centre, 375 South Street, London, ON, N6A 4G5, Canada. Charles.George@LHSC.ON.CA
Publication date & source: 2011-01, Sleep Breath., 15(1):13-20. Epub 2010 Jan 18.
Publication type: Comparative Study; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
PURPOSE: Sodium oxybate (SXB) is approved for cataplexy and excessive daytime sleepiness in narcolepsy. Obstructive sleep apnea syndrome (OSAS) affects approximately 9-50% of narcoleptics. Effects of 2-week SXB administration on apnea-hypopnea index (AHI), oxygen saturation (SaO(2)), and sleep architecture were investigated in OSAS patients. METHODS: OSAS patients (n = 48) received 2-week SXB or placebo (PBO) treatment with polysomnography at baseline and day 14. The primary outcome measure was change from baseline in mean AHI. Secondary outcomes included changes from baseline in SaO(2), and sleep architecture. RESULTS: Compared with PBO, SXB significantly increased reduction in mean AHI and obstructive apnea index with SXB (-0.8 +/- 13.3 vs. -8.2 +/- 10.0; p = 0.0327 and 3.54 +/- 11.1 vs. -4.72 +/- 7.7; p = 0.0054, respectively) and significantly increased change in slow wave sleep duration (5.2 +/- 25.0 min vs. 29.4 +/- 37.0 min; p = 0.0038). There were no differences between treatments in SaO2, central apneic events, or other measures. Adverse events, most commonly headache, were noted in nine of 27 (33%) and six of 23 (26%) patients receiving SXB and PBO, respectively. CONCLUSIONS: Short-term use of 4.5 g/night SXB did not generate respiratory depressant effects in OSAS patients as measured by AHI, obstructive apnea events, central apneas, and SaO2. Extended use of SXB in higher therapeutic doses in OSAS has not been studied, and merits caution.